Five Prime Therapeutics (FPRX) Earning Favorable Media Coverage, Accern Reports

Media coverage about Five Prime Therapeutics (NASDAQ:FPRX) has been trending positive on Friday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a news impact score of 0.32 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 59 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern’s rankings:

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Several equities research analysts have recently issued reports on the stock. Jefferies Group LLC reissued a “buy” rating and set a $55.00 price objective on shares of Five Prime Therapeutics in a research report on Monday, May 15th. Instinet assumed coverage on shares of Five Prime Therapeutics in a research report on Wednesday, March 1st. They set a “buy” rating and a $94.00 price objective for the company. Nomura assumed coverage on shares of Five Prime Therapeutics in a research report on Wednesday, March 1st. They set a “buy” rating for the company. ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, TheStreet downgraded shares of Five Prime Therapeutics from a “c” rating to a “d+” rating in a research report on Monday, March 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $60.83.

Five Prime Therapeutics (NASDAQ:FPRX) traded down 0.70% on Friday, reaching $31.24. 560,380 shares of the company were exchanged. The company’s 50-day moving average price is $29.79 and its 200-day moving average price is $40.02. Five Prime Therapeutics has a 12-month low of $26.65 and a 12-month high of $60.98. The stock’s market capitalization is $871.50 million.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.25. Five Prime Therapeutics had a negative return on equity of 21.81% and a negative net margin of 250.98%. The firm had revenue of $10.13 million during the quarter, compared to analysts’ expectations of $6.05 million. During the same quarter in the previous year, the business earned ($0.49) earnings per share. The company’s revenue for the quarter was up 55.8% compared to the same quarter last year. Equities research analysts anticipate that Five Prime Therapeutics will post ($4.67) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Five Prime Therapeutics (FPRX) Earning Favorable Media Coverage, Accern Reports” was originally posted by Mideast Time and is the property of of Mideast Time. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.mideasttime.com/five-prime-therapeutics-fprx-earning-favorable-media-coverage-accern-reports/1806695.html.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:FPRX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.